Clinical trial
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects…
NCT01681953 · Zymenex A/S, Industry · Completed
Key facts
| NCT number | NCT01681953 |
|---|---|
| Title | A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis |
| Official title | A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis. |
| Lead sponsor | Zymenex A/S, Industry |
| Collaborators | European Commission |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alpha-Mannosidosis |
| Intervention type | Drug |
| Interventions | Lamazym, Placebo |
| Enrollment | 25 |
| Start date | Aug 1, 2012 |
| Primary completion | May 1, 2014 |
| Completion | May 1, 2014 |
| First posted | Sep 10, 2012 |
| Last update posted | Aug 3, 2020 |
| Countries | Denmark, France, Germany, Poland, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: